EGFR-TKIs including erlotinib and gefitinib (first-generation reversible), afatinib (second-generation irreversible), osimertinib (third-generation irreversible) have been approved for the treatment of lung cancer patients harboring EGFR mutations47–50, and cetuximab has been used for HNSCC and colorectal cancer patients19,20,51. Here, EGFR is linked to head and neck squamous cell carcinoma.